SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MEDX ... anybody following?
MEDX 31.58+1.4%Nov 5 12:44 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (685)6/19/2003 12:24:01 PM
From: keokalani'nui  Read Replies (1) of 2240
 
It's small trial, P1 etc. etc.

This part sounds pretty good:

>>In a pooled analysis of all dose cohorts, ACR20 response (from week 0) was achieved in 15 of 24 patients (63%), ACR50 in 38% and ACR70 in 25%.<<

But these aspects don't:

--infusion
--pts not on other DMARDS, so comparison looks better than in practice
--single loading dose and 4 subsequent weekly doses doesn't sound like it would be popular

Have no idea whether anti-IL-15 would serve an unserved market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News